Side-by-side · Research reference

ChonlutenvsMelanotan-II

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BPhase 1HUMAN-REVIEWED9/43 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

Melanotan-II

MC1R + MC4R agonist · Tanning + sexual response

0.25–1.0 mgPer doseDorr 1996

Phase 1Evidence levelDorr 1996

~1 hrHalf-life

SQ · Abdomen · Loading 5–7 days, then maintenance

01Mechanism of Action

Parameter

Chonluten

Melanotan-II

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996 Simerly 2023

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996

Feedback intact?

—

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

Melanotan-II

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

Daily during loading; 1–2× per week maintenance

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Phase 1 + anecdotalDorr 1996

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

8–12 weeks per cycle

Clinical validation

None (PubMed indexed)

—

Loading phase

—

0.25–0.5 mg/day SQ × 5–7 daysDorr 1996

Builds up to visible tan.

Maintenance

—

0.5–1.0 mg 1–2×/week

After visible tan develops; supports with UV exposure.

Lower / starter dose

—

0.1 mg / day

Conservative starter — assess tolerability for nausea.

Reconstitution

—

Bacteriostatic water; protect from light

Timing

—

Evening preferred (24h tan-development cycle)

Half-life

—

~1 hour plasma; effects on melanocytes persist days

04Side Effects & Safety

Parameter

Chonluten

Melanotan-II

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Nausea

—

Common, especially loading phase

Flushing

—

Common transient

Spontaneous erection

—

Common in men — MC4R cross-effectDorr 1996

Increased mole / freckle pigmentation

—

Existing moles darken; new lesions possible

Melanoma risk

—

Theoretical concern — increased melanocyte activity; CAUTION in melanoma history

Appetite suppression

—

MC4R-mediated; mild

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

Melanotan-II

·History of melanoma or atypical mole syndrome
·Pregnancy / breastfeeding
·Active uncontrolled hypertension

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

Melanotan-II

·Significant freckling / dysplastic nevus
·Personal or family melanoma history

05Administration Protocol

Parameter

Chonluten

Melanotan-II

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

SQ — abdomen. Rotate sites.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

29–31G insulin syringe.